Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial

Aim The Counterweight‐Plus weight management programme achieved 46% remission of Type 2 diabetes at 1 year in the DiRECT trial. We estimated the implementation costs of the Counterweight‐Plus programme and its 1‐year cost‐effectiveness in terms of diabetes remission, compared with usual care, from t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetic medicine 2019-08, Vol.36 (8), p.1003-1012
Hauptverfasser:	Xin, Y., Davies, A., McCombie, L., Briggs, A., Messow, C.‐M., Grieve, E., Leslie, W. S., Taylor, R., Lean, M. E. J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antihypertensives Cost control Cost-Benefit Analysis Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - economics Diabetes Mellitus, Type 2 - therapy Diet - economics Evidence-based medicine Facilities and Services Utilization General Practice - economics General Practice - statistics & numerical data Hospitalization - economics Hospitalization - statistics & numerical data Humans Hypertension Hypoglycemic Agents - economics Hypoglycemic Agents - therapeutic use Nutrient deficiency Patient Acceptance of Health Care - statistics & numerical data Primary Health Care - economics Remission State Medicine - economics Weight Reduction Programs - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!